Back to News
Market Impact: 0.2
Roche Collaborator MediLink Says Tam-Peli Achieves 54% OS Risk Reduction In Phase III SCLC Trial
Source: Nasdaq
Healthcare & Biotech
Roche collaborator MediLink released interim results from the randomized Phase III TAISHAN-302 trial of Tam-Peli (tambotatug pelitecan, YL201) versus topotecan in Chinese patients with relapsed small-cell lung cancer. The provided article excerpt does not disclose efficacy, safety, or statistical outcome data, limiting assessment of the trial's financial or clinical impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- This hospice services stock is outperforming the S&P 500. Jefferies sees more gains ahead
- Waters’ new AI tool targets one of the pharmaceutical industry’s most tedious tasks
- Biotechs buck a sluggish IPO market, but investors should tread warily
- Dassault Systèmes raises 2026 outlook as revenue growth rebound gathers pace
- Needham initiates Clover Health stock with buy on cohort economics